Development and evaluation of Nurse Practitioner follow-up in the management of patients with lung cancer.

ISRCTN	ISRCTN64726310
DOI	https://doi.org/10.1186/ISRCTN64726310
Protocol serial number	NCP/J17/18
Sponsor	Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)
Funder	NHS Cancer National Research and Development Programme (UK)

Submission date: 23/01/2004
Registration date: 23/01/2004
Last edited: 22/05/2012

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Cancer

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Jessica Corner
Scientific

The Institute of Cancer Research
The Centre for Cancer and Palliative Care Studies
Royal Cancer Hospital
Fulham Road
London
SW3 6JJ
United Kingdom

Phone	+44 (0)20 7352 8171

Study information

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title
Study objectives	Not provided at time of registration
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Cancer (neoplasms): Lung (non-small cell)
Intervention	1. Conventional medical follow-up: At the specialist cancer hospital, patients were seen within one month and, if stable, discharged back to their referring cancer unit. At the cancer units, follow-up was 2 - 3 monthly if patients were stable. At all centres, patients who were not considered medically stable were seen on the basis of need. 2. Nurse-led follow-up: Patients allocated to one of two Clinical Nurse Specialists (CNS) who took responsibility for their follow-up care for one year. Patients assessed monthly or on basis of need by telephone or at a nurse-led clinic. Patients could also use a paging system to contact CNS if they had concerns during intervals between assessments. Focus of care was not only disease surveillance but also the physical, psychological and social needs of patients and their families. Emphasis on prompt communication and liaison with primary care teams. Patients attended hospital medical clinics only if their condition indicated this was needed or if patients requested a consultation with a hospital physician.
Intervention type	Other
Primary outcome measure(s)	Not provided at time of registration
Key secondary outcome measure(s)	Not provided at time of registration
Completion date	01/01/2001

Eligibility

Participant type(s)	Patient
Age group	Not Specified
Sex	Not Specified
Key inclusion criteria	1. Patients with lung cancer having completed initial treatment 2. Not requiring immediate medical intervention or close medical supervision 3. Considered to have a good performance status (World Health Organization [WHO] performance status 0 - 2) 4. Had an expected prognosis of at least 3 months 5. Were not participating in other clinical trials requiring intensive medical investigation or follow-up 6. Understood and read English for informed consent and data collection purposes
Key exclusion criteria	Not provided at time of registration
Date of first enrolment	01/01/1999
Date of final enrolment	01/01/2001

Locations

Countries of recruitment

United Kingdom
England

Study participating centre

The Institute of Cancer Research

London
SW3 6JJ
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	16/11/2002		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes